 CytoDyn Inc OTCQB:CYDY has announced that a clinical trial for its flagship drug candidate, leronlimab, has advanced from Phase 1b to a Phase 2 study. The leronlimab trial is being carried out in combination with carboplatin for the treatment of metastatic triple-negative breast cancer mTNBC. 